MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle Indications for CARTISTEM®2023/12/27STEM CELL THERAPEUTIC
MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery Clinical Study Results Published in SCI-Level Journal2023/05/02STEM CELL THERAPEUTIC
MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, Accelerating Clinical Development efforts in Japan2023/01/16STEM CELL THERAPEUTIC
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022/07/18STEM CELL THERAPEUTIC
MEDIPOST gears up to enter the global SMUP-IA-01 market based on clinical results in Korea2022/04/01STEM CELL THERAPEUTIC
MEDIPOST’s treatment for knee osteoarthritis, enters phase 3 clinical trials in Japan2022/03/25STEM CELL THERAPEUTIC
MEDIPOST’s injectable drug for knee osteoarthritis, SMUP-IA-01, enters phase 2 clinical trials in Korea2021/12/24STEM CELL THERAPEUTIC
MEDIPOST receives approval to proceed with phase 2 clinical trial in Korea for its next-generation injectable drug for knee osteoarthritis, SMUP-IA-012021/10/27STEM CELL THERAPEUTIC
MEDIPOST requests approval for the phase 2 clinical trial in Korea of its next-generation injectable drug for knee osteoarthritis, SMUP-IA-012021/07/30STEM CELL THERAPEUTIC
MEDIPOST presents the development progress of its next-generation injectable drug for knee osteoarthritis in the Spring Conference of the Korean Orthopedic Surgeons Association2021/07/09STEM CELL THERAPEUTIC
MEDIPOST completes the expansion of its GMP facilities for CARTISTEM, a stem cell therapy, and SMUP-IA-01, an injectable knee osteoarthritis treatment2021/05/17STEM CELL THERAPEUTIC
MEDIPOST’s phase 1 clinical trial results for its injectable drug for knee osteoarthritis in Korea show improvements in safety and clinical symptoms2021/03/22STEM CELL THERAPEUTIC
